5 Stocks Likely To Move Big On An Early-Stage Readout
We used our BPIQ platform to identify biopharma stocks with early-stage readout and are likely to move big. Usually stock-moving readouts are late stage trials; but here are 5 stocks we've identified, likely to move on early-stage readouts. See the table and text below for more details.
$IMTX
ACTengine® IMA203 GEN1 | Melanoma | Ph1b
ACTengine® IMA203 is an autologous T cell product with a genetically modified, pairing-enhanced TCR directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). Ph1b data at SMR 2024 on 10/11.
$IRON
DISC-0974 | Anemia in NDD-CKD | Ph1b/2
DISC-0974 is an investigational monoclonal antibody (mAb) targeting a BMP-signaling co-receptor hemojuvelin (HJV) designed to suppress hepcidin production and increase serum iron levels.
$RCUS
Casdatifan/AB521 | ccRCC | Ph1
Casdatifan/AB521 is a small molecule inhibitor of the oxygen-sensing transcription factor HIF-2⍺ that has demonstrated potent antitumor activity in xenograft models of renal cell cancer (RCC). ORR and safety data from 100mg expansion cohort in H2 2024.
$TYRA
TYRA-300 | Solid Tumors | Ph1/2
TYRA-300 is an investigational, oral, FGFR3-selective inhibitor being evaluated in a multi-center, open label Phase 1/2 clinical study, SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumors). Initial Ph1 results in H2 2024. Addresses two critical limitations of current approved and investigational FGFR inhibitors: selectivity & resistance.
$VKTX
VK2735 | Obesity | Ph1
VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. 100-mg dose-escalation data and Ph2 initiation by Q4 2024.
Want to see all smid cap biotech future movers in October?
Become a BPIQ Elite member & get the full list. We identify events that can drive significant price moves! 🚀
#IMTX #IRON #RCUS #TYRA #VKTX
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 09/24/24 JD, SK, & EJV